Company: TG Therapeutics
Job title: Vice President, Preclinical Sciences
Emmanuel Normant is currently the vice president of preclinical sciences at TG Therapeutics, a biotech focused on heme malignancies and located in New York.
There, he oversees the early pipeline that includes a novel BTK inhibitor, an anti-PD-1 antibody and a bispecific antibody directed against CD19 and CD47. All three drugs are currently tested in phase 1 dose-escalation clinical trials in hematologic cancers.
Dr Normant joined TG Therapeutics two years ago, bringing in 20 years expertise in cancer biology, pharmacology, immuno-oncology, cancer epigenetic and preclinical sciences.
Emmanuel Normant received his pharmacy and PhD degrees from Paris-Sorbonne university.
Enhancing Clinical Efficacy with Macrophage Checkpoint Blockades in Combination Therapies 9:00 am - 12:00 pm
Join this workshop to: Review TG-1801 which is a novel, bispecific antibody currently in Phase 1 that selectively targets CD47 on CD19+ B-cells, sparing red blood cells or platelets, and blocking the CD47-SIRPα macrophage checkpoint on B cells Evaluate results that set the preclinical rationale for a combination strategy of the novel CD47-CD19 antibody TG-1801…Read more